The National Institute for Health and Care Excellence (NICE) has provisionally announced that Kadcyla, a drug used to treat an aggressive form of breast cancer, is too expensive for routine use within the NHS in England. The decision means that around 1,200 patients each year who could potentially benefit from the treatment may not be able to access it through standard NHS pathways.
Kadcyla, also known as trastuzumab emtansine, is a targeted therapy designed for patients with HER2-positive advanced breast cancer that has spread to other parts of the body and has progressed despite initial treatment with other anti-HER2 drugs. Clinical trials have shown that Kadcyla can extend life by several months compared to other available treatments, and it can also offer a better quality of life by potentially reducing the need for more aggressive chemotherapy regimens.
NICE's role is to evaluate the clinical and cost-effectiveness of new drugs and treatments for the NHS. While acknowledging Kadcyla's clinical benefits, the organisation concluded that the drug's price, estimated to be over £90,000 per patient for a course of treatment without a discount, was too high to justify its routine use within the NHS budget. This assessment considers the additional years of life gained and the quality of those years in relation to the cost, a metric known as the Quality-Adjusted Life Year (QALY).
Roche, the pharmaceutical company that manufactures Kadcyla, has expressed significant disappointment with NICE's provisional decision. The company has stated its commitment to continuing discussions with NICE and NHS England to explore potential solutions, including a revised pricing structure, to ensure that eligible patients in England can access the drug. Similar discussions have often led to agreements in the past, where drug manufacturers offer confidential discounts to make treatments more affordable for the health service.
This provisional rejection highlights the ongoing tension between the need to provide innovative, life-extending treatments and the financial constraints faced by the NHS. The decision will now enter a consultation period, during which patient groups, clinicians, and the manufacturer can submit further evidence and arguments for NICE to consider before making a final recommendation. Patients currently receiving Kadcyla through interim funding arrangements are typically not affected by such decisions immediately, but future access for new patients could be impacted.
For patients and their families, this news can be distressing. It underscores the challenges in accessing cutting-edge cancer treatments and the importance of continued dialogue between pharmaceutical companies, health authorities, and patient advocates to find viable solutions. The broader implications for the NHS involve balancing the introduction of new, often expensive, therapies with the equitable provision of care across all conditions.